Glucose Tolerance in Healthy Overweight Adults

Overview

The primary objective is to compare the postprandial glycemic response of healthy overweight adults after consuming an amino acid drink mix versus a control drink.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 2009

Interventions

  • Other: Amino Acid Drink Mixture
    • 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
  • Other: Glucose drink
    • 22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins

Arms, Groups and Cohorts

  • Experimental: AA Drink
    • Amino Acid Drink Mixture
  • Placebo Comparator: Glucose drink

Clinical Trial Outcome Measures

Primary Measures

  • The primary variable is the positive area under the curve from 0 to 180 minutes for plasma glucose.
    • Time Frame: 0-180 minutes

Secondary Measures

  • Plasma glucose, insulin, C-peptide, free fatty acids, and glucagon concentration data over time
    • Time Frame: 0-180 minutes

Participating in This Clinical Trial

Inclusion Criteria

1. Fasting blood glucose level of ≥ 70mg/dL and ≤ 125 mg/dL. 2. Subject states that he/she does not have type 1 or 2 diabetes. 3. Subject is overweight as defined as waist circumference ≥ 101 cm (40 inches) male; ≥ 88 cm (35 inches) female. 4. Subject's BMI is ≥ 25 kg/m2. 5. Subject's blood pressure is < 140 mm Hg systolic and < 90 mm Hg diastolic. 6. Subject is between 20 and 45 years of age, inclusive. 7. Subject is a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit. 8. If female is of childbearing potential, is practicing birth control 9. If subject is on a chronic medication such as a thyroid medication or hormone therapy, has been on constant dosage for at least two months prior to screening visit. Exclusion Criteria:

1. Subject is eating a low carbohydrate diet such as Atkins, Zone, or South Beach diet plan. 2. Subject states that he/she has current infection, has had inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks prior to screening visit. 3. Subject states that he/she has an active malignancy. 4. Subject states that he/she has had a significant cardiovascular event ≤ six months prior to screening visit; or stated history of congestive heart failure. 5. Subject states that he/she has end-stage organ failure or is status post organ transplant. 6. Subject states that he/she has a history of renal disease. 7. Subject states that he/she has current hepatic disease. 8. Subject states that he/she has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. 9. Subject has taken/is currently taking any herbals, dietary supplements, or medications during the past four weeks prior to screening visit that could profoundly affect blood glucose. 10. Subject has taken/is currently taking any herbals, dietary supplements, or medications during the past four weeks prior to screening visit to control hypertension or cholesterol. 11. Subject states that he/she has clotting or bleeding disorders.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Abbott Nutrition
  • Provider of Information About this Clinical Study
    • Bobbie L Swearengin, RN, Abbott Nutrition
  • Overall Official(s)
    • Jeffrey Nelson, PhD, Study Chair, Abbott Nutrition

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.